نتایج جستجو برای: plerixafor

تعداد نتایج: 455  

Journal: :Haematologica 2017
Maria Rosa Lidonnici Annamaria Aprile Marta Claudia Frittoli Giacomo Mandelli Ylenia Paleari Antonello Spinelli Bernhard Gentner Matilde Zambelli Cristina Parisi Laura Bellio Elena Cassinerio Laura Zanaboni Maria Domenica Cappellini Fabio Ciceri Sarah Marktel Giuliana Ferrari

For decades, bone marrow (BM) has been the preferred source of hematopoietic stem and progenitor cells (HSPCs) for transplants following myeloablative conditioning. At present, mobilized peripheral blood stem cells are commonly used for transplantation, particularly in the autologous setting. 1 Hematopoietic stem cells (HSCs) are maintained in their niche by binding to adhesion molecules and di...

2011
Boryana E Avramova Maya N Yordanova Dobrin N Konstantinov Dragan G Bobev

This paper describes the successful mobilization of peripheral blood stem cells for autologous transplantation in three children with malignant diseases by using plerixafor (Mozobil; Genzyme Corporation, Cambridge, MA) and granulocyte-colony stimulating factor (G-CSF) after failed previous mobilizations. A median sixfold increase in the number of circulating CD34+ cells after plerixafor treatme...

Journal: :Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2013
Simon P Fricker

Autologous hematopoietic stem cell (HSC) transplantation is an important therapeutic option for patients with non-Hodgkin's lymphoma and multiple myeloma. The primary source of HSC is from the peripheral blood which requires mobilization from the bone marrow. Current mobilization regimens include cytokines such as G-CSF and/or chemotherapy. However not all patients mobilize enough HSC to procee...

2012
Susan Slater

Author's disclosures of potential conflicts of interest are found at the end of this article. S ince the early 1980s, high-dose chemotherapy followed by autologous hematopoi-etic stem cell transplantation (HSCT) has emerged as standard therapy for patients with hematologic ma-lignancies, including non-Hodgkin lymphoma (NHL) and multiple myelo-ma (MM). In 2009, 32,000 autologous transplants were...

2016
Adan Rios Sigmund H. Hsu Angel Blanco Jamie Buryanek Arthur L. Day Mary F. McGuire Robert E. Brown

UNLABELLED Glioblastoma multiforme (GBM) is a CNS (central nervous system) malignancy with a low cure rate. Median time to progression after standard treatment is 7 months and median overall survival is 15 months [1]. Post-treatment vasculogenesis promoted by recruitment of bone marrow derived cells (BMDCs, CD11b+ myelomonocytes) is one of main mechanisms of GBM resistance to initial chemoradio...

2012
Kyung Taek Hong Hyoung Jin Kang Nam Hee Kim Min Sun Kim Ji Won Lee Hyery Kim Kyung Duk Park Hee Young Shin Hyo Seop Ahn

Peripheral blood stem cell (PBSC) mobilization, which uses plerixafor (AMD 3100), a newly developed specific inhibitor of the CXCR4 receptor, in combination with granulocyte-colony stimulating factor(G-CSF), has been shown to enhance the stem cell mobilization in adult patients, but pediatric data are scarce. We documented our experience with this drug in 6 Korean pediatric patients who had fai...

Journal: :Blood 2009
Pablo Ramirez Michael P Rettig Geoffrey L Uy Elena Deych Matthew S Holt Julie K Ritchey John F DiPersio

Here we show that interruption of the VCAM-1/VLA-4 axis with a small molecule inhibitor of VLA-4, BIO5192, results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels. An additive affect on HSPC mobilization (3-fold) was observed when plerixafor (AMD3100), a small molecule inhibitor of the CXCR-4/SDF-1 axis, was combined with BIO5192. Fur...

2011
Louis M Pelus Sherif S Farag

Multiple myeloma and non-Hodgkin's lymphoma remain the most common indications for high-dose chemotherapy and autologous peripheral blood stem cell rescue. While a CD34+ cell dose of 1 × 10(6)/kg is considered the minimum required for engraftment, higher CD34+ doses correlate with improved outcome. Numerous studies, however, support targeting a minimum CD34+ cell dose of 2.0 × 10(6)/kg, and an ...

2010

The drug and the review Plerixafor was licensed in the UK in August 2009 to be used in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly. The recommended dose of plerixafor is 0.24mg/kg body weight per day (to a max...

2016
Michael M B Green Nelson Chao Saurabh Chhabra Kelly Corbet Cristina Gasparetto Ari Horwitz Zhiguo Li Jagadish Kummetha Venkata Gwynn Long Alice Mims David Rizzieri Stefanie Sarantopoulos Robert Stuart Anthony D Sung Keith M Sullivan Luciano Costa Mitchell Horwitz Yubin Kang

BACKGROUND The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSCT) promotes hematopoiesis by inducing HSC proliferation. METHODS We conducted a phase I/II trial of plerixafor on hematopoietic cell recover...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید